Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papi (Ferrara, Italy), N. Barnes (Brentford, Middlesex & London, United Kingdom), A. Fowler (Brentford, Middlesex, United Kingdom), H. Kerstjens (Groningen, Netherlands), E. Kerwin (Medford, OR, United States of America), D. Mannino (Lexington, KY & Research Triangle Park, NC, United States of America), R. Nathan (Colorado Springs, CO, United States of America), I. Pavord (Oxford, United Kingdom), E. Pizzichini (Brentford, Middlesex & Santa Catarina, United Kingdom), D. Slade (Research Triangle Park, NC, United States of America), A. Zarankaite (Brentford, Middlesex, United Kingdom), J. Oppenheimer (Newark, NJ, United States of America). CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes. 1487

Member's Comments

No comment yet.

Related content which might interest you: CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Predicting IPF outcomes: lung function evaluation by %predicted and z-score Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 A statistical model to estimate lung density (LD) utilizing oscillometry (OS), biometrics (BM), patient reported outcomes (PRO) and pulmonary function tests (PFT) Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Post-bronchodilator response (PBDR) evaluated by plethysmographic and spirometric target parameters in patients with COPD, asthma-COPD-overlap (ACO) and asthma Source: International Congress 2018 – Innovations in equipment and their application Year: 2018 Correlation between single items in COPD assessment test (CAT) and outcome parameters of pulmonary rehabilitation (PR) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Short term change in modified BODE (mBODE) in severe emphysema patients predicts mortality with lung volume reduction surgery (LVRS) Source: Eur Respir J 2006; 28: Suppl. 50, 569s Year: 2006 Differences between % predicted and z-score. The impact on severity classification in spirometry. Source: Virtual Congress 2020 – Quality improvements in lung function and sleep diagnostics Year: 2020 Prediction of all cause mortality in a population sample is improved by using FEV1 quotient Source: Annual Congress 2005 - Assessing the relevance of obstructive airway diseases Year: 2005 Prospective analysis of lung function in COPD patients – home monitoring of FEV1 and PEF (PIKO®1) Source: Eur Respir J 2006; 28: Suppl. 50, 108s Year: 2006 Exercise testing to predict lung cancer surgery outcome: which is better - percentage of predicted VO2 or absolute value? Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 The relationship between peak expiratory flow rate (PEFR) and forced expiratroy volume in the first second (FEV1) at low levels of FEV1. Implications for the assessment of COPD (chronic obstructive pulmonary disease) in primary care Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Effect of polymeric lung volume reduction (PLVR) therapy on composite COPD outcome measures Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 Correlation of nutritional status using subjective global assessment (SGA) on pulmonary function parameters in patients with COPD at the Philippine Heart Center Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 CAT (COPD assessment test) as outcome parameter of pulmonary rehabilitation (PR) in COPD Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life Year: 2011 The effects of standard therapy for COPD patients on FEV1 are associated with lower score of the Goddard classification Source: International Congress 2014 – Multidimensional analysis of respiratory problems Year: 2014 Percent predicted forced vital capacity (FVC) is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis Year: 2010 Has the determination of the rate of decline of FEV1 added value in addition to the determination of FEV1/FVC and FEV1 Source: International Congress 2016 – Man versus machine: waves, frequency, and more in lung function Year: 2016